Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia

AIM OF THE STUDY: Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Styczyński, Jan, Gil, Lidia, Czyżewski, Krzysztof, Kołodziej, Beata, Kuryło-Rafińska, Beata, Lewandowski, Krzysztof, Gniot, Michał, Lewandowska, Maria, Komarnicki, Mieczysław, Wysocki, Mariusz
Format: Artigo
Jezik:Inglês
Izdano: Termedia Publishing House 2012
Teme:
Original Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3687416/
https://ncbi.nlm.nih.gov/pubmed/23788881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2012.29286
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki